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ABSTRACT
Background n-3 fatty acids inhibit neuronal excitability
and reduce seizures in animal models. High-dose ﬁsh oil
has been explored in two randomised trials in drug
resistant epilepsy with negative results. We performed a
phase II randomised controlled crossover trial of low-
dose and high-dose ﬁsh oil in participants with drug
resistant epilepsy to explore whether low-dose or high-
dose ﬁsh oil reduces seizures or improves cardiovascular
health.
Methods Randomised placebo-controlled trial of low-
dose and high-dose ﬁsh oil versus placebo (corn oil,
linoleic acid) in 24 participants with drug resistant
epilepsy. A three-period crossover design was utilised
lasting 42 weeks, with three 10-week treatment periods
and two 6-week washout periods. All participants were
randomised in double-blind fashion to receive placebo,
high dose or low dose in different sequences. The
primary outcome was per cent change in total seizure
frequency.
Findings Low-dose ﬁsh oil (3 capsules/day, 1080 mg
eicosapentaenoic acid+docosahexaenoic acid) was
associated with a 33.6% reduction in seizure frequency
compared with placebo. Low-dose ﬁsh oil was also
associated with a mild but signiﬁcant reduction in blood
pressure. High-dose ﬁsh oil was no different than placebo
in reducing seizures or improving cardiac risk factors.
Interpretation In this phase II randomised crossover
trial, low-dose ﬁsh oil was effective in reducing seizures
compared with placebo. The magnitude of improvement
is similar to that of recent antiepileptic drug trials in drug
resistant epilepsy (DRE). The results indicate that low-dose
ﬁsh oil may reduce seizures and improve the health of
people with epilepsy. These ﬁndings justify a large
multicentre randomised trial of low-dose ﬁsh oil (n-3 fatty
acids <1080 mg/day) in drug resistant epilepsy.
Trial registration number NCT00871377.
INTRODUCTION
Drug resistant epilepsy is a serious disease, deﬁned
as failure of a patient with epilepsy to respond to
two or more appropriate antiepileptic drugs at a
therapeutic dose.1 Treatment options include
adding new antiepileptic drugs, followed by consid-
eration of epilepsy surgery, neuromodulation or
dietary therapy (ketogenic diet or the modiﬁed
Atkins diet).1–4 Fish oil, which contains ω-3 fatty
acids (n-3 fatty acids), is of particular interest
because it may improve cardiac health, reduce
sudden cardiac death after myocardial infarction
and delay the onset of seizures in a pentylenetetra-
zole model of acute seizures.5 6 n-3 fatty acids,
especially docosahexaenoic acid (DHA), cross the
blood brain barrier and become incorporated into
the cell membrane’s lipid bi-layer.5 There, n-3 fatty
acids are believed to modify calcium and sodium
channels, reducing membrane excitability in heart
myocytes and neurons.7 8 Randomised controlled
clinical trials of high-dose ﬁsh oil have been per-
formed with promising, yet inconclusive results.9 10
The purpose of this clinical trial is to evaluate high-
dose and low-dose ﬁsh oil in a phase II randomised
placebo-controlled crossover trial in participants
with drug resistant epilepsy.
METHODS
Study design
The study design is a prospective, randomised,
three-period crossover clinical trial of two doses of
ﬁsh oil: low dose, high dose or placebo, in partici-
pants with drug resistant partial-onset seizures
(simple partial, complex partial or secondary gener-
alised tonic–clonic seizures). The study design is
summarised in ﬁgure 1.
Since all participants are on placebo during one
of the three periods, there is no placebo pretreat-
ment period. All treatment comparisons for efﬁcacy
are between treatment with ﬁsh oil (high or low
dose) and placebo. This strategy was chosen to
reduce the total duration of the trial, which is
already long at 42 weeks. For vital signs, heart rate
variability (HRV) and laboratory measures, visit 1
serves as the pretreatment baseline.
The intervention was Pharmavite ‘Nature Made’
ﬁsh oil capsules. Each ﬁsh oil capsule contained
216 mg of eicosapentaenoic acid (EPA) and 144 mg
of DHA, for a total of 360 mg n-3 fatty acids per
capsule. The low-dose group received a total n-3
dose=1080 mg/day (three ﬁsh oil capsules per day)
and the high-dose group received a total n-3
dose=2160 mg/day (three ﬁsh oil capsules twice a
day). The placebo was a capsule identical in appear-
ance, taste and odour containing corn oil (no EPA
or DHA), equal to three corn oil capsules twice a
day. Corn oil was selected as a placebo since it is
ubiquitous in the American diet, and has no antie-
pileptic effect.11 All three capsules were adminis-
tered in gel form orally, twice a day. To maintain
blind interactions, the low-dose group received
three ﬁsh oil capsules and three corn oil capsules
per day, to keep the number of capsules the same
between groups. An independent laboratory
certiﬁed that the study drug contained no poly-
hlorinated biphenyl (PCBs) or heavy metals (certiﬁ-
cate of analysis on ﬁle, principal investigator).
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The study was funded by a research grant from the National
Institutes of Health/National Center for Complementary and
Alternative Medicine (NCCAM). An investigational new drug
application (IND) was obtained from the US Food and Drug
Administration (FDA) prior to initiation of the study. Signed
informed consent was obtained from the participants at the
time of enrolment. The study was registered at clinicaltrials.gov
(NCT00871377).
Participants were evaluated in the UCLA General Clinical
Research Center on enrolment, and at the beginning and end of
each 10-week treatment period. A period of 6 weeks duration
occurred between each treatment period to allow the effects of
the study intervention to washout before beginning a new treat-
ment period. The total study duration for each participant was
42 weeks (ﬁgure 1).
On entry, and at the beginning of each treatment period, vital
signs, history, physical examination, Chalfont Seizure Severity
Scale, 1 h cardiac Holter monitoring for HRV, complete blood
count, chemistry panel, lipid panel and C reactive protein were
obtained. Seizure calendars were reviewed and validated by the
study physician at each visit. No medication changes were
allowed during the study unless absolutely needed for partici-
pant safety.
Inclusion and exclusion criteria
The inclusion criteria required for study entry were as follows:
male or female, age 18–70; history of drug resistant localiza-
tion-related partial onset or generalised tonic/clonic seizures
deﬁned according to the International League Against Epilepsy
(ILAE) classiﬁcation: speciﬁcally, a history compatible with
localisation-related or partial epilepsy, and an EEG and/or a
MRI of the brain consistent with a localisation-related or partial
epilepsy; three or more simple partial, complex partial or tonic–
clonic seizures per month; evidence of at least three seizures per
month for at least 2 months prior to the study; prior exposure
to at least three antiepileptic drugs in therapeutic doses or con-
centrations alone or in combination at least one trial of two
concurrent antiepileptic drugs at therapeutic doses or
concentrations; concurrent therapy with at least one antiepilep-
tic drug at therapeutic doses or concentrations.
The exclusion criteria were as follows: signiﬁcant or progres-
sive medical, cardiac or other illness; allergy to ﬁsh products or
ﬁsh oil; history of a coagulation disorder; history of
non-epileptic seizures; consumption of ﬁsh oil at any time
30 days or less prior to enrolment; any change in antiepileptic
drugs for 30 days or fewer prior to enrolment; treatment with
warfarin or daily aspirin for 30 days or fewer prior to enrol-
ment; previous poor compliance with therapy; alcohol or drug
misuse; uncountable seizures as a result of seizure clustering, or
inadequate supervision if the patient could not count their own
seizures.
Randomisation
Participants were randomised in blocks of four to a crossover
sequence of low dose, high dose and placebo. All participants
were randomised once they met inclusion criteria at visit 1, and
entered the initial 10-week treatment period. Entry into the
study was followed by a 6-week washout period, and again a
10-week treatment period, followed by a second 6-week
washout period, and then a ﬁnal 10-week treatment period.
Participants were randomised to six possible sequences (see
ﬁgure 1). The entire duration of the study was 42 weeks.
Statistical analysis
Seizures were obtained from participant seizure calendars, and
calculated in seizures per day for each treatment period, then
computed as seizures per month, where a month is deﬁned as
28 days. Repeated-measure models for crossover designs were
used to compare seizure rates or means. The model included a
treatment effect (treatment 1, 2 or 3), period effect (A, B or C)
and treatment×period interaction (non-parallelism), and
allowed for the non-independence (correlations) of multiple
observations from the same patient.
Study design and primary outcome measure
The primary end point was per cent change in total seizure fre-
quency for low-dose ﬁsh oil or high-dose ﬁsh oil versus placebo.
Total seizure frequency was deﬁned as the total number of
countable and stereotyped simple partial, complex partial and
generalised tonic/tonic–clonic seizures. The null hypothesis was
that the per cent change in seizure frequency during treatment
with ﬁsh oil was not different from placebo.
Data for the primary outcome, total seizure frequency, con-
formed to a negative binomial distribution. Therefore, a
repeated-measure negative binomial model was used to compare
seizure frequency rates using maximum likelihood to compute p
values. For secondary outcomes (mean arterial pressure (MAP),
heart rate, Chalfont Seizure Severity Scale, measures of HRV
(including RMSSD, SDNN, SDANN), lipids, C reactive protein),
examination of quantile plots indicated that the residual errors
for the secondary outcomes conformed to Gaussian (normal) dis-
tributions. Therefore, the conventional parametric mixed-model
repeated-measure analysis of variance (ANOVA) was used to
compare means and compute p values for these outcomes. For
SDNN, SDAAN, RMSSD, pulse and MAP, results were deter-
mined following subtraction of the initial baseline only, and, in a
separate analysis, subtraction of the ‘local’ baseline at the start of
each period (visit 1, visit 4, visit 7). For total cholesterol, low-
density lipoprotein (LDL), high-density lipoprotein (HDL) and
triglycerides, there was no local baseline at visit 4. A participant
was considered to have a 50% reduction in seizure rate under
low dose if the seizure rate under low dose was at least 50%
Figure 1 (A) Study ﬂow. (B) Possible treatment allocations and
sequences.
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lower than the seizure rate under placebo, regardless of treatment
period order. The same deﬁnition applied to the high-dose treat-
ment condition.
RESULTS
Participant characteristics
Table 1 summarises the clinical data of the participant cohort.
The average age of the participants was 33 years, SD 10.33.
Sixteen participants were women, and eight participants were
men. Forty-six participants were screened for the study; 25 met
criteria and were enrolled. Twenty-four participants received at
least one dose of the study medication. Figure 2 shows the
CONSORT ﬂow diagram for the study.
Primary end point: per cent change in total seizure
frequency
The average seizure frequency during low-dose ﬁsh oil treatment
was 12.18 (SE 2.72) vs 17.67 seizures/month (SE 4.56) for high-
dose ﬁsh oil, and 18.34 seizures/month (SE 4.28) for placebo.
The difference in seizure frequency between low-dose ﬁsh oil
and placebo was −33.6%, p=0.02. Seizure frequency under
high-dose ﬁsh oil was similar to that of placebo, with no signiﬁ-
cant difference between high dose and placebo, p=0.82.
Low-dose ﬁsh oil was associated with a 31% reduction in
seizure frequency compared with high-dose ﬁsh oil (borderline
signiﬁcant, p=0.05).
For low-dose ﬁsh oil, 5/20 (25%) experienced a 50% reduc-
tion in seizures compared with placebo. Three of 20 (15%)
exposed to high-dose ﬁsh oil experienced a 50% reduction in
seizures compared with placebo. Two participants were seizure
free during treatment with low-dose ﬁsh oil (2/20, 10%). No
participants were seizure free during treatment with placebo or
high-dose ﬁsh oil (all comparisons, p=0.22–0.48, Fisher exact
test). Table 2 summarises the data for the primary and key sec-
ondary efﬁcacy outcomes.
Low-dose ﬁsh oil was associated with an average reduction of
1.95 mm Hg (SE=1.91 mm Hg) in MAP from baseline, which
was signiﬁcantly less than high-dose ﬁsh oil (1.84 mm Hg
average increase, SE=1.90 mm Hg, p=0.03), but similar to the
effect of the placebo (2.31 mm Hg decrease, SE=1.89 mm Hg,
p=0.83, ANOVA). For the low-dose ﬁsh oil treatment, there
was a trend towards improved high-frequency HRV (RMSSD
+4.97 ms, p=0.09; RMSSD is a measure of the integrity of
vagus nerve control of the heart). Fish oil was not associated
with signiﬁcant improvements or changes in heart rate, HRV,
lipids (total cholesterol, HDL, LDL or triglycerides) or Seizure
Severity Score. Table 2 summarises the major primary and sec-
ondary ﬁndings of the study.
Adverse events
Fish oil was well tolerated, with no serious adverse events
encountered during the study. One participant died during the
study due to autopsy-conﬁrmed sudden death in epilepsy
(SUDEP). This participant was in the high-dose ﬁsh oil treat-
ment period when SUDEP occurred. At the same time, the par-
ticipant was on multiple antiepileptic drugs and aripiprazole, an
antipsychotic also associated with an increase in cardiac mortal-
ity. The patient had failed epilepsy surgery, vagal nerve stimula-
tion, had frequent tonic–clonic seizures and was found after a
seizure next to his bed in the prone position. The cause of death
was thought by the investigator to be unrelated to the treatment
with ﬁsh oil.
Table 1 Summary of participant clinical data
N Age Sex Type Duration (years) Number of AED’s Localisation Aetiology
Baseline
seizure frequency
1 32 M CPS, GTC 14 3 TLE, bilateral Head trauma 3/month
2 28 F CPS, GTC 7 2 TLE, bilateral Encephalitis
3 56 F SPS 44 2 TLE, right Unknown 5/month
4 44 M SPS, CPS, GTC 33 1 TLE, left Febrile 6/month
5 37 M SPS 15 3 Left occipital Unknown 300/month
6 32 M SPS, CPS, GTC 31 2 Non-localised Febrile illness 3/month
7 24 M SPS 10 2 L temporal Unknown 12/month
8 45 M CPS, GTC 45 4 R parietal Cortical dysplasia 6/month
9 28 F LGS DROP, MYOCLONIC
GTC
28 2 Bilateral LGS, translocation X chromosome 20/month
10 19 M SPS, GTC 5 3 Bilateral Unknown 60/month
11 22 F SPS
CPS
12 3 Right temporal Unknown 4/month
12 37 F CPS 7 2 Right temporal Unknown 5/month
13 18 F CPS, GTC 17 3 Non-localised Unknown 24/month
14 30 M CPS, GTC 22 4 Bilateral Hypoxic ischaemia birth injury Unknown
15 40 F CPS 34 2 Right temporal Familial TLE
16 32 F SPS, GTC 10 1 Temporal lobe Unknown 10/month
17 34 F SPS, CPS, GTC 29 3 Non-localised Birth injury 5/month
18 42 F SPS, CPS 30 2 Bilateral temporal Unknown 30/month
19 46 F SPS, CPS, 31 2 Left temporal Ganglioglioma 3/month
20 28 F SPS, GTC 20 1 Unknown Head trauma 8/month
21 30 M SPS, CPS, GTC 26 3 Left temporal Birth injury 15/month
22 21 M CPS, GTC 16 4 Unknown Cortical dysplasia 60/month
24 22 F SPS, CPS, 17 1 Unknown Unknown 10/month
25 53 F CPS 13 2 Bitemporal Unknown 13/month
AED, antiepileptic drug; CPS, complex partial seizures; GTC, generalized tonic clonic seizures; LGS, Lennox Gastaut syndrome; SPS, simple partial seizures; TLE, temporal lobe epilepsy.
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DISCUSSION
The primary ﬁnding is that low-dose ﬁsh oil (3 capsules/day,
1080 mg of EPA+DHA) was associated with a reduction in
seizure frequency of −33.6% compared with placebo. Low-dose
ﬁsh oil was associated with a responder rate of 25% and a
seizure-free rate of 10%. Though the size of the trial will
require conﬁrmation, the magnitude of the effect on seizure fre-
quency is similar to many randomised trials of antiepileptic
drugs.2
Low-dose ﬁsh oil was also associated with a modest reduction
in blood pressure, but this ﬁnding was signiﬁcant only when
compared with high-dose ﬁsh oil. The reduction in blood pres-
sure indicates that low-dose ﬁsh oil may exert a positive cardio-
vascular beneﬁt in this cohort with drug resistant epilepsy, a
ﬁnding of some importance, given the recent data that the risk
of death due to myocardial infarction is signiﬁcantly higher in
people with epilepsy.12
To date, there have been two major randomised controlled
trials of n-3 fatty acids for epilepsy, both of which used higher
doses. In 2005, Yuen et al9 ﬁrst reported a randomised placebo-
controlled parallel trial of ﬁsh oil for epilepsy in 58 participants
with epilepsy, in which 1700 mg of EPA+DHA was
Figure 2 CONSORT ﬂow diagram. PI,
principal investigator; SUDEP, sudden
death in epilepsy.
Table 2 Summary of efficacy data—means or proportions
Fish oil
3 capsules/day
1080 mg
n-3 FAs/day
Fish oil
6 capsules/day
2160 mg
n-3 FAs /day
Placebo
corn oil p Value*
Seizures/month 12.18*
SE 2.72
17.67
SE 4.56
18.34
SE 4.28
*0.02
Seizure, per cent change from placebo −33.6%* −3.6% – *0.02
Responder rate 25%
SE 9.7%
15%
SE 8.4%
NA NS
Seizure-free rate 10.0% 0% 0% NS
Mean change blood pressure from pretreatment visit 1 (MAP, mm Hg) −1.95
SE 1.91
+1.84
SE 1.90
−2.31
SE 1.89
<0.03, Low dose vs high dose
High-frequency heart rate variability, RMMSD
Mean change from pretreatment visit 1 (milliseconds)
+4.97
SE 2.95
+1.18
SE 2.91
−0.41
SE 2.85
0.09, Low dose vs placebo
SEs are in parenthesis. Low dose comparison to placebo unless otherwise indicated.
*refers to the difference between low dose fish oil and placebo.
FA, fatty acid; MAP, mean arterial blood pressure; NA, not applicable; NS, not significant.
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administered daily. No side effects or antiepileptic drug interac-
tions were reported. Initially, a signiﬁcantly higher number of
participants on ﬁsh oil experienced a greater than 50% reduc-
tion in seizures in the ﬁrst 6 weeks of the treatment period;
however, over the entire 12-week treatment period, there was
no signiﬁcant difference in responder rate for the treatment
versus control.9 Between-group differences in seizure frequen-
cies at baseline may have made it difﬁcult to detect true differ-
ences, a phenomenon common in epilepsy clinical trials.9 In
2008, Bromﬁeld et al10 reported a randomised controlled trial
in 21 participants with drug resistant epilepsy using a higher
dose of ﬁsh oil (2200 mg/day of EPA and DHA). During the
acute treatment period, ﬁsh oil supplementation was associated
with an increased seizure frequency of 6% versus a reduction of
12% with placebo.10 However, after conclusion of the 12-week
randomised trial, long-term treatment was associated with sig-
niﬁcant reductions in seizures, with 5/19 participants experien-
cing a 50% reduction in seizures, many of whom (4/5) were
originally randomised to placebo.10
Fish oil is safe and well tolerated. The US FDA designates ﬁsh
oil at doses of 3 g/day as ‘Generally Recognized as Safe’
(GRAS).13 Recently, plasma n-3 fatty acid levels (not ﬁsh oil sup-
plementation) have been associated with an increased risk of
prostate cancer.14 This ﬁnding is controversial, as dietary sources
of n-3 fatty acids include smoked ﬁsh, high in nitrates and
nitrites, well known to increase the risk of prostate cancer.15
Recently, a large trial found that ﬁsh oil consumption in later life
is protective against prostate cancer.15 More research on the link
between n-3 fatty acids and prostate cancer is needed.
Data from several large well-executed double-blind studies
have shown that ﬁsh oil supplementation or a diet high in n-3
fatty acids reduce mortality after myocardial infarction.5 6 16
These data have led the American Heart Association to issue the
following statement:
Evidence from prospective secondary prevention studies suggests
that EPA and DHS supplementation ranging from 0.5 to 1.8 g/d
(either as fatty ﬁsh oil supplements) signiﬁcantly reduces subse-
quent cardiac and all cause mortality.16
The large GISSI Prevenzioni study showed that n-3 fatty acids
at 1150 mg/day (similar to our low dose of 1060 mg/day) signiﬁ-
cantly reduced mortality and sudden cardiac death compared
with placebo.6 Similarly, Singh et al17 demonstrated that a higher
dose of n-3 fatty acids (2 g EPA/DHA/day) signiﬁcantly reduced
cardiac-related deaths after myocardial infarction at 1 year by
nearly 50%. Recently, a meta-analysis and interventional trial of
ﬁsh oil failed to demonstrate a consistent reduction in cardiovas-
cular risk.18 19 However, a large prospective study of multiethnic
Americans found a signiﬁcant protective effect of ﬁsh oil intake,
n-3 fatty acid levels and cardiovascular risk.20 A second
meta-analysis found that ﬁsh oil signiﬁcantly reduces the risk of
cardiovascular disease.21 The authors note that the earlier
meta-analysis included studies of very low dose n-3 fatty acids
(<500 mg/day), which may have been subtherapeutic.21 Given
the conﬂicting studies, clariﬁcation of the role and optimum dose
of ﬁsh oil in cardiovascular disease is needed.18–21
The lack of efﬁcacy of high-dose ﬁsh oil in this trial is consist-
ent with data from recent animal studies. Acute administration
of high-dose n-3 fatty acids (DHA, 600 mg/kg) exacerbates sei-
zures in a pentylenetetrazole model.22 This is in direct contrast
to lower doses of DHA (<400 mg/kg), which exhibit an anti-
convulsant effect.2 Similarly, rats, which are genetically resistant
to seizures, experience a signiﬁcant increase in susceptibility to
kindling when exposed to high-dose ﬁsh oil (1000 mg/kg of
EPA, 700 mg/kg of DHA).23 The authors hypothesise that the
increased susceptibility to high-dose n-3 fatty acids may be par-
tially due to excessive reductions in non-esteriﬁed fatty acids
(eg, arachidonic acid).23
The relative efﬁcacy of low-dose ﬁsh oil compared with high-
dose ﬁsh oil has also been reported in clinical trials in major
depressive disorder.24 Depressed participants experience signiﬁ-
cant improvements in mood following supplementation with
low-dose n-3 fatty acids (1 g of EPA/day), but no improvement
with high dose (2 or 4 g of EPA/day).24 The response to ﬁsh oil
at low dose for seizures and depression have substantial implica-
tions for use, given the common propensity for individuals to
self-dose with ‘a little helps, a lot should help much more’
thought process. The dose–response ﬁndings also raise substan-
tial implications for mechanisms of action, which must be better
understood if ﬁsh oil interventions be considered for epilepsy.
It is important that the results from this trial be conﬁrmed in
a large multicentre trial. Limitations include the relatively short
duration of exposure; participants were only exposed to each
treatment for 10 weeks. It is unknown whether the improve-
ment in seizures for the low-dose group is sustained over time.
Second, due to the crossover design, a pretreatment baseline
was not incorporated. This was designed to minimise the time
where participants were held captive in the study without treat-
ment, due to the already long duration of the study (42 weeks).
However, since the study was a double-blind placebo-controlled
crossover design, all comparisons were made to a true placebo.
A large conﬁrmatory study will likely use a traditional parallel
group design with a pretreatment baseline.
Finally, the study did include three participants who had exclu-
sively simple partial seizures. Inclusion of participants with
partial seizures is common in antiepileptic drug studies.
However, these participants were highly drug resistant, and their
response did not contribute to efﬁcacy demonstrated by ﬁsh oil,
as none experienced more than a 17% reduction in seizures.
In summary, we report that low-dose ﬁsh oil (3 capsules/day,
total of 1080 mg EPA+DHA) was associated with a 33.6%
reduction in seizure frequency compared with placebo in a
cohort with drug resistant epilepsy, and a mild but signiﬁcant
reduction in blood pressure. A large randomised controlled trial
of ﬁsh oil is warranted to conﬁrm or refute the ﬁndings of this
study. Low-dose ﬁsh oil is a safe and low-cost intervention that
may reduce seizures and improve cardiovascular health in
people with epilepsy.
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